| Overview |
| bs-70067S |
| Dopamine ß-Hydroxylase, C-Terminus Antibody |
| WB |
| Specific for endogenous levels of the ~75 kDa DBH protein. |
| Human, Mouse, Non-Human Primate |
| Specifications |
| Unconjugated |
| Sheep |
| Synthetic peptide from the C-terminal region of human dopamine β-hydroxylase (DBH), conjugated to keyhole limpet hemocyanin (KLH). |
| Polyclonal |
| IgG |
| Lot Dependent |
| Antigen Affinity purification from Pooled whole antiserum |
| 10 mM HEPES (pH 7.5), 150 mM NaCl, 100 µg per ml BSA and 50% glycerol. |
| Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C. |
| Target |
| 1621 |
| P09172 |
| dbh antibody, DBM antibody, Dopamine beta hydroxylase antibody, Dopamine beta monooxygenase antibody, Dopamine beta-hydroxylase (dopamine beta-monooxygenase) antibody, Dopamine beta-monooxygenase antibody, DOPO_HUMAN antibody, OTTHUMP00000022501 antibody, Soluble dopamine beta-hydroxylase antibody |
| DBH catalyzes the conversion of dopamine to norepinephrine and serves as a marker of noradrenergic cells. DBH antibodies and antibodies for other markers of catecholamine biosynthesis are widely used as markers for dopaminergic and noradrenergic neurons in a variety of applications including depression, schizophrenia, Parkinson’s disease and drug abuse (Kish et al., 2001; Zhu et al., 2000; Zhu et al., 1999). The expression of DBH is also elevated during stress (Sabban and Kvetnansky, 2001). |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz